Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 61, Issue 2, 2002, Pages 121-127

  Dick, T ^a   Mierau, R ^a   Bartz Bazzanella, P ^b   Alavi, M ^c   Stoyanova Scholz, M ^d   Kindler, J ^e   Genth, E ^a  

^a Rheumaklinik   (Germany)

^b St Antonius Hospital   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d Klinikum Duisburg   (Germany)

^e Kreiskrankenhaus Würselen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; DNA TOPOISOMERASE; DNA TOPOISOMERASE ANTIBODY; ENZYME ANTIBODY; HLA ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ALLELISM; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ANALYSIS; HLA TYPING; HUMAN; IMMUNOBLOTTING; IMMUNODIFFUSION; IMMUNOFLUORESCENCE; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA; SCREENING TEST; SYSTEMIC SCLEROSIS;

ADULT; AUTOANTIBODIES; CENTROMERE; DNA TOPOISOMERASES, TYPE I; HUMANS; IMMUNOLOGIC TESTS; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 0036153449     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.2.121     Document Type: Article

References (76)

1. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
2. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis
3. Autoantibodies in systemic sclerosis
4. Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology
5. Antinuclear antibody in systemic sclerosis (scleroderma)
6. Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population
7. Anticentromere antibodies (ACA): Clinical distribution and disease specificity
8. Antinuclear antibodies in patients with Raynaud's phenomenon: Clinical significance of anticentromere antibodies
9. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: Nuclear immunofluorescence patterns and ELISA reactivities
10. Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus
11. Clinical correlation of anticentromere antibodies
12. Test performance in systemic sclerosis: Anti-centromere and anti-Scl-70 antibodies
13. Antinuclear antibodies in progressive systemic sclerosis
14. Immunological markers of the subsets of systemic scleroderma and its overlap
15. Immunogenetic association of scleroderma-related antinuclear antibodies
16. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma)
17. Association of amino add sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis)
18. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
19. Clinical relevance and HLA association of autoantibodies against the nucleolus organizer region (NOR-90)
20. Autoantibodies in the diagnosis of systemic rheumatic diseases
21. Antihistone antibodies in systemic sclerosis: Association with pulmonary fibrosis
22. Coexistence of CREST syndrome and primary biliary cirrhosis. Serological studies of two cases
23. Anti-cardiolipin antibodies and other immunological disorders in patients with systemic scleroderma
24. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies
25. Systemic sclerosis sine scleroderma - Demographic, clinical, and serologic features and survival in forty-eight patients
26. Autoantibody reactive with RNA polymerase III in systemic sclerosis
27. Autoantibodies in scleroderma
28. Are ACA and Scl-70 antibodies mutually exclusive?
29. Systemic sclerosis: An autoantibody mosaic
30. Pulmonale manifestation bei progressiver, systemischer sklerodermie: Prognostische werligkeit der zentromerantikörper und antikörper gegen Scl-70 nukleoprotein
31. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis
32. Clinical subsets of scleroderma: Relevance of fluorescent and precipitating antinuclear antibodies
33. Analysis of autoantibodies against RNA polymerases using immunoaffinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay
34. Anti-CENP-B response in sera of uranium miners exposed to quartz dust and patients with possible development of systemic sclerosis (scleroderma)
35. The use of immunoblotting to detect antibodies to nuclear and cytoplasmic antigens. Clinical and serological associations in rheumatic diseases
36. Marker antibodies in scleroderma and polymyositis: Clinical associations
37. HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies
38. Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin)
39. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients
40. Cutaneous and serologic subsets of systemic sclerosis
41. Les sclérodermies masculines: Rô1e de l'exposition professionnelle
42. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35
43. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis
44. Type III collagen aminopropeptide and laminin P1 levels in serum of patients with silicosis-associated and idiopathic systemic scleroderma
45. Silica-induced scleroderma
46. A patient with systemic sclerosis, severe cytopenias and the simultaneous presence of anti-centromere and anti-Scl-70-antibodies
47. Association of anti-U1RNP-and anti-Scl-70-antibodies with neurological manifestations in systemic sclerosis (scleroderma)
48. Clinical significance of antinuclear antibodies in Japanese patients with systemic sclerosis
49. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis
50. Scl 70 antibody - A specific marker of systemic sclerosis
51. Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: Comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion
52. Autoanticorps anti-Scl-70 et anti-centromère. Marquers biologiques de 2 variétés différentes de sclérodermie systémique
53. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: A six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting
54. The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays
55. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody
56. Kernantikörper als serologische marker der progressiv systemischen sklerodermie (PSS)
57. A case of rheumatoid arthritis associated with progressive systemic sclerosis and primary biliary cirrhosis in the presence of various autoantibodies
58. Anticentromere antibody: Clinical correlation and association with favorable prognosis in patients with scleroderma variants
59. Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: A serological and HLA study
60. A highly conserved 72,000 dalton centromeric antigen reactive with autoantibodies from patients with progressive systemic sclerosis
61. Racial differences in antinuclear antibody patterns and clinical manifestation of scleroderma
62. Zentromerantikörper und Antikörper gegen Scl-70-Nucleoprotein bei progressiver systemischer Sklerose
63. Coexistence of anti centromere and anti topoisomerase I antibodies in a patient with silica-induced scleroderma
64. Serological profiles as prognostic clues for progressive systemic scleroderma: The Italian experience
65. Clinical setting of patients with systemic sclerosis by serum autoantibodies
66. Anticorps anti-centromères. Étude de 67 sérums positifs
67. Association of anti-centromere and anti-Scl-70 antibodies in scleroderma. Report of two cases
68. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis
69. A case of systemic sclerosis with anticentromere, antitopoisomerase I, and anti-UIRNP antibodies
70. Hydrochloric acid treatment of HEp-2 cells for the detection of masked anticentromere antibody (ACA)
71. Eukaryotic expression of recombinant human centromere autoantigen and its use in a novel ELISA for diagnosis of CREST Syndrome
72. Diversity of antinuclear antibodies in progessive systemic sclerosis
73. Scl-86, a marker antigen for diffuse scleroderma
74. Patients with anticentromere antibodies, clinical features, diagnoses and evolution
75. Anticentromere antibodies: Clinical correlates
76. Clinical association of anticentromere antibodies and antibodies to topoisomerase I